Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts
Analysts believe that US efforts to blacklist Chinese pharmaceutical firms, including WuXi AppTec, will have minimal impact due to cost advantages. Despite the US Department of Defense adding WuXi AppTec to an updated list of "Chinese military companies," multinational drug makers are expected to continue prioritizing Chinese manufacturing for cost efficiency. Previous legislative attempts to ban contracts with similar firms also saw company names removed before enactment, suggesting a continued preference for cost-effective production in the healthcare sector. AI
IMPACT Minimal direct impact on AI operators; focuses on supply chain and regulatory policy in the pharmaceutical sector.